{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:45:24Z","timestamp":1777934724823,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.contraception.2022.09.129","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T06:50:38Z","timestamp":1665557438000},"page":"67-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Contraception claims by medication for opioid use disorder prescription status among insured women with opioid use disorder, United States, 2018"],"prefix":"10.1016","volume":"117","author":[{"given":"Sonal","family":"Goyal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Monsour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Y.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn M.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura K.","family":"Whiteman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey C.","family":"Coy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shanna","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-3522","authenticated-orcid":false,"given":"Lisa","family":"Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.contraception.2022.09.129_bib0001","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jpag.2017.11.002","article-title":"A retrospective chart review of contraceptive use among adolescents with opioid use disorder","volume":"31","author":"Handy","year":"2018","journal-title":"J Pediatr Adolesc Gynecol"},{"issue":"11","key":"10.1016\/j.contraception.2022.09.129_bib0002","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1080\/10826084.2016.1188944","article-title":"Family planning in substance use disorder treatment centers: opportunities and challenges","volume":"51","author":"Robinowitz","year":"2016","journal-title":"Subst Use Misuse"},{"issue":"3","key":"10.1016\/j.contraception.2022.09.129_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116231","article-title":"Contraceptive use and pregnancy outcomes among opioid drug-using women: a retrospective cohort study","volume":"10","author":"Cornford","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.contraception.2022.09.129_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ypmed.2015.04.008","article-title":"Contraceptive use and method choice among women with opioid and other substance use disorders: A systematic review","volume":"80","author":"Terplan","year":"2015","journal-title":"Prev Med. Nov"},{"key":"10.1016\/j.contraception.2022.09.129_bib0005","article-title":"Innovative approaches to reduce unintended pregnancy and improve access to contraception among women who use opioids","volume":"128","author":"Heil","year":"2019","journal-title":"Prev Med. Nov"},{"issue":"9","key":"10.1016\/j.contraception.2022.09.129_bib0006","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1056\/NEJMsa1506575","article-title":"Declines in unintended pregnancy in the United States, 2008-2011","volume":"374","author":"Finer","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.contraception.2022.09.129_bib0007","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/jama.2020.24991","article-title":"Neonatal abstinence syndrome and maternal opioid-related diagnoses in the US, 2010-2017","volume":"325","author":"Hirai","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2022.09.129_bib0008","doi-asserted-by":"crossref","unstructured":"American college of obstetricians and gynecologists. committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol. Aug 2017;130(2):e81-e94. doi: 10.1097\/aog.0000000000002235","DOI":"10.1097\/AOG.0000000000002235"},{"issue":"3","key":"10.1016\/j.contraception.2022.09.129_bib0009","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/ADM.0000000000000308","article-title":"Treating women who are pregnant and parenting for opioid use disorder and the concurrent care of their infants and children: literature review to support national guidance","volume":"11","author":"Klaman","year":"2017","journal-title":"J Addict Med"},{"issue":"9","key":"10.1016\/j.contraception.2022.09.129_bib0010","doi-asserted-by":"crossref","first-page":"242","DOI":"10.15585\/mmwr.mm6609a2","article-title":"CDC grand rounds: public health strategies to prevent neonatal abstinence syndrome","volume":"66","author":"Ko","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5","key":"10.1016\/j.contraception.2022.09.129_bib0011","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-029074","article-title":"Committee on fetus and newborn, committee on substance use and prevention. Neonatal opioid withdrawal syndrome","volume":"146","author":"Patrick","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.contraception.2022.09.129_bib0012","unstructured":"Substance Abuse and Mental Health Services Administration. Medications for opioid use disorder TIP 63 treatment improvement protocol for healthcare and addiction professionals, policymakers, patients, and families. Substance Abuse and Mental Health Services Administration. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Available at: https:\/\/store.samhsa.gov\/sites\/default\/files\/SAMHSA_Digital_Download\/PEP21-02-01-002.pdf; 2021 [accessed 24 January 2022]."},{"key":"10.1016\/j.contraception.2022.09.129_bib0013","series-title":"White Paper: IBM MarketScan Research Databases for life sciences researchers","author":"Hansen","year":"2018"},{"issue":"3","key":"10.1016\/j.contraception.2022.09.129_bib0014","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10900-019-00781-z","article-title":"The teen access and quality initiative: improving adolescent reproductive health best practices in publicly funded health centers","volume":"45","author":"Brittain","year":"2020","journal-title":"J Community Health"},{"key":"10.1016\/j.contraception.2022.09.129_bib0015","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Arlington, VA, American Psychiatric Association; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.contraception.2022.09.129_bib0016","unstructured":"U.S. Federal Food and Drug Administration. Information about Medication-Assisted Treatment (MAT). Available at: https:\/\/www.fda.gov\/drugs\/information-drug-class\/information-about-medication-assisted-treatment-mat; Last updated February 14, 2019 [accessed 30 July 2021]"},{"key":"10.1016\/j.contraception.2022.09.129_bib0017","unstructured":"Trussell J, Aiken ARA, Micks E, Guthrie KA. Efficacy, safety, and personal considerations. In: Hatcher RA, Nelson AL, Trussell J, Cwiak C, Cason P, Policar MS, Edelman A, Aiken ARA, Marrazzo J, Kowal D, eds. Contraceptive technology. 21st ed. New York, NY: Ayer Company Publishers, Inc.; 2018."},{"issue":"3","key":"10.1016\/j.contraception.2022.09.129_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6503a1","article-title":"US Medical Eligibility Criteria for Contraceptive Use","volume":"65","author":"Curtis","year":"2016","journal-title":"MMWR Recomm Rep"},{"issue":"2","key":"10.1016\/j.contraception.2022.09.129_bib0019","first-page":"65","article-title":"A Simple Sequentially Rejective Multiple Test Procedure","volume":"6","author":"Holm","year":"1979","journal-title":"Scandinavian J Statistics"},{"issue":"4","key":"10.1016\/j.contraception.2022.09.129_bib0020","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/GRF.0000000000000059","article-title":"Contraceptive counseling: best practices to ensure quality communication and enable effective contraceptive use","volume":"57","author":"Dehlendorf","year":"2014","journal-title":"Clin Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.contraception.2022.09.129_bib0021","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.2105\/AJPH.2016.303393","article-title":"Provider bias in long-acting reversible contraception (LARC) promotion and removal: perceptions of young adult women","volume":"106","author":"Higgins","year":"2016","journal-title":"Am J Public Health"},{"key":"10.1016\/j.contraception.2022.09.129_bib0022","doi-asserted-by":"crossref","unstructured":"Madras BK, Ahmad NJ, Wen J, Sharfstein JS. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect. 2020 Apr 27;2020:10.31478\/202004b. doi: 10.31478\/202004b. PMID: 35291732","DOI":"10.31478\/202004b"},{"issue":"9","key":"10.1016\/j.contraception.2022.09.129_bib0023","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.contraception.2022.09.129_bib0024","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2018.06.006","article-title":"Treatment outcome disparities for opioid users: Are there racial and ethnic differences in treatment completion across large US metropolitan areas?","volume":"190","author":"Stahler","year":"2018","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.contraception.2022.09.129_bib0025","unstructured":"United States Government Accountability Office. Opioid Addiction: Laws, regulations and other factors can affect medication-assisted treatment access. Available at: https:\/\/www.gao.gov\/assets\/gao-16-833.pdf September 2016. [Accessed 16 June 2022]."},{"issue":"2","key":"10.1016\/j.contraception.2022.09.129_bib0026","first-page":"S63","article-title":"Factors affecting contraception access and use in patients with opioid use disorder","volume":"60","author":"Stone","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.contraception.2022.09.129_bib0027","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.whi.2019.08.005","article-title":"Perceived barriers and facilitators to contraceptive use among women veterans accessing the veterans affairs healthcare system","volume":"30","author":"Wolgemuth","year":"2020","journal-title":"Womens Health Issues"},{"issue":"1","key":"10.1016\/j.contraception.2022.09.129_bib0028","first-page":"27","article-title":"Improving access to long-acting contraceptive methods and reducing unplanned pregnancy among women with substance use disorders","volume":"10","author":"Black","year":"2016","journal-title":"Subst Abuse"},{"issue":"5","key":"10.1016\/j.contraception.2022.09.129_bib0029","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.whi.2021.03.010","article-title":"Reproductive-age women\u2019s experience of accessing treatment for opioid use disorder: \u201cWe Don\u2019t Do That Here\u201d","volume":"31","author":"Phillippi","year":"2021","journal-title":"Womens Health Issues"},{"issue":"3","key":"10.1016\/j.contraception.2022.09.129_bib0030","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s11606-020-06257-4","article-title":"Barriers and facilitators to the use of medications for opioid use disorder: a rapid review","volume":"35","author":"Mackey","year":"2020","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.contraception.2022.09.129_bib0031","unstructured":"Orgera K, Tolbert J. Key facts about uninsured adults with opioid use disorder. Henry J Kaiser Family Foundation, Available at: https:\/\/files.kff.org\/attachment\/Data-Note-Key-Facts-about-Uninsured-Adults-with-Opioid-Use-Disorder; 2019."},{"key":"10.1016\/j.contraception.2022.09.129_bib0032","series-title":"Revisiting Churn: An Early Understanding of State-Level Health Coverage Transitions Under the ACA","year":"2016"},{"key":"10.1016\/j.contraception.2022.09.129_bib0033","series-title":"Health Insurance Coverage Among Young Adults Aged 19 to 34: 2018 and 2019","author":"Conway","year":"2020"},{"issue":"2","key":"10.1016\/j.contraception.2022.09.129_bib0034","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1177\/003335491012500209","article-title":"Condoms for dual protection: patterns of use with highly effective contraceptive methods","volume":"125","author":"Pazol","year":"2010","journal-title":"Public Health Rep"},{"issue":"RR-5","key":"10.1016\/j.contraception.2022.09.129_bib0035","first-page":"1","article-title":"Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: Summary guidance from CDC and the U.S. Department of Health and Human Services","volume":"61","year":"2012","journal-title":"MMWR Recomm Rep"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782422003894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782422003894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:21:47Z","timestamp":1757881307000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782422003894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":35,"alternative-id":["S0010782422003894"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2022.09.129","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contraception claims by medication for opioid use disorder prescription status among insured women with opioid use disorder, United States, 2018","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2022.09.129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}